Using RPPA data obtained from the LPT1090906 neoadjuvant clinical trial [18], only 2 of the 13 (15.4%) cancers treated with lapatinib alone had decreased p-AKT levels following 14 days of treatment. This evidence concerns the gene AKT1 and cancer.